Using Radiomics and Machine Learning Applied to MRI to Predict Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer.
MRI
cervical cancer
gynecology oncology
neoadjuvant chemotherapy
radiomics
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
06 Oct 2023
06 Oct 2023
Historique:
received:
15
08
2023
revised:
25
09
2023
accepted:
03
10
2023
medline:
14
10
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Neoadjuvant chemotherapy plus radical surgery could be a safe alternative to chemo-radiation in cervical cancer patients who are not willing to receive radiotherapy. The response to neoadjuvant chemotherapy is the main factor influencing the need for adjunctive treatments and survival. In the present paper we aim to develop a machine learning model based on cervix magnetic resonance imaging (MRI) images to stratify the single-subject risk of cervical cancer. We collected MRI images from 72 subjects. Among these subjects, 28 patients (38.9%) belonged to the "Not completely responding" class and 44 patients (61.1%) belonged to the 'Completely responding' class according to their response to treatment. This image set was used for the training and cross-validation of different machine learning models. A robust radiomic approach was applied, under the hypothesis that the radiomic features could be able to capture the disease heterogeneity among the two groups. Three models consisting of three ensembles of machine learning classifiers (random forests, support vector machines, and k-nearest neighbor classifiers) were developed for the binary classification task of interest ("Not completely responding" vs. "Completely responding"), based on supervised learning, using response to treatment as the reference standard. The best model showed an ROC-AUC (%) of 83 (majority vote), 82.3 (mean) [79.9-84.6], an accuracy (%) of 74, 74.1 [72.1-76.1], a sensitivity (%) of 71, 73.8 [68.7-78.9], and a specificity (%) of 75, 74.2 [71-77.5]. In conclusion, our preliminary data support the adoption of a radiomic-based approach to predict the response to neoadjuvant chemotherapy.
Identifiants
pubmed: 37835882
pii: diagnostics13193139
doi: 10.3390/diagnostics13193139
pmc: PMC10572442
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Ultrasound. 2021 Dec;24(4):429-437
pubmed: 32696414
J Clin Oncol. 2018 Jun 1;36(16):1548-1555
pubmed: 29432076
Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):546-553
pubmed: 28011045
Gynecol Oncol. 2021 Jun;161(3):838-844
pubmed: 33867144
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Anticancer Res. 2020 Sep;40(9):4819-4828
pubmed: 32878770
Front Oncol. 2020 Feb 04;10:77
pubmed: 32117732
J Clin Oncol. 2000 Apr;18(8):1606-13
pubmed: 10764420
Gynecol Oncol. 2004 Jul;94(1):61-6
pubmed: 15262120
Radiol Med. 2022 May;127(5):498-506
pubmed: 35325372
J Magn Reson Imaging. 2018 May;47(5):1388-1396
pubmed: 29044908
J Clin Med. 2023 Feb 09;12(4):
pubmed: 36835908
Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1446-50
pubmed: 23704476
Healthcare (Basel). 2022 Dec 07;10(12):
pubmed: 36553988
Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3643-3655
pubmed: 33959797
Radiol Clin North Am. 2023 Jul;61(4):749-760
pubmed: 37169435
Am J Clin Oncol. 2010 Dec;33(6):583-6
pubmed: 20065848
Eur J Nucl Med Mol Imaging. 2013 May;40(5):716-27
pubmed: 23340594
J Clin Oncol. 2023 Sep 1;:JCO2202852
pubmed: 37656948
J Natl Compr Canc Netw. 2019 Jan;17(1):64-84
pubmed: 30659131
Gynecol Oncol. 1990 Sep;38(3):352-7
pubmed: 2227547
Ultrasound Obstet Gynecol. 2022 Aug;60(2):256-268
pubmed: 34714568
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):169-76
pubmed: 16427212
JAMA Oncol. 2016 Dec 01;2(12):1636-1642
pubmed: 27541161
Int J Gynecol Cancer. 2018 May;28(4):641-655
pubmed: 29688967
Eur Radiol Exp. 2021 Jul 26;5(1):28
pubmed: 34308487
Int J Gynecol Cancer. 2023 Jul 3;33(7):1070-1076
pubmed: 37094971
Int J Gynaecol Obstet. 2019 Apr;145(1):129-135
pubmed: 30656645